CDKN2A and Miyoshi myopathy: Of interest, DNA hypermethylation of the cell cycle inhibitors p15 and p16, cyclin-dependent kinase inhibitor 2A (CDKN2A), and TGFBR2 has been associated with poor prognosis in MM patients [27, 32, 34, 35].